|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0005740,
umls-concept:C0010583,
umls-concept:C0016441,
umls-concept:C0019829,
umls-concept:C0023972,
umls-concept:C0030705,
umls-concept:C0032952,
umls-concept:C0033223,
umls-concept:C0042679,
umls-concept:C0279264,
umls-concept:C1512162,
umls-concept:C1517942,
umls-concept:C1522449
|
|
pubmed:issue |
3-4
|
|
pubmed:dateCreated |
2001-6-27
|
|
pubmed:abstractText |
Thirty-three evaluable patients with Hodgkin's disease who failed radiotherapy were treated on this phase II study with bleomycin, lomustine, cyclophosphamide, vincristine, procarbazine and prednisone given every 28 days for a minimum of eight courses. Twenty-five patients (76%; 95% CI=55.6-87.1%) achieved a complete remission, the median duration of which cannot yet be determined, but the probability of remaining in continuous complete remission at 10 years is.64. The median survival from entry on this study for all evaluable patients is 10 years, and 12 patients were alive at the time of this analysis with a median follow-up for them of 15.5 years. Of the 22 patients who died, 11 died of progressive or recurrent Hodgkin's disease and 11 died of other causes including 7 second primary neoplasms and at least one myocardial infarction. Both are now well known late complications of Hodgkin's disease treatment.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
1042-8194
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
40
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
357-63
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:11426558-Adolescent,
pubmed-meshheading:11426558-Adult,
pubmed-meshheading:11426558-Aged,
pubmed-meshheading:11426558-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:11426558-Bleomycin,
pubmed-meshheading:11426558-Cause of Death,
pubmed-meshheading:11426558-Cohort Studies,
pubmed-meshheading:11426558-Cyclophosphamide,
pubmed-meshheading:11426558-Female,
pubmed-meshheading:11426558-Hodgkin Disease,
pubmed-meshheading:11426558-Humans,
pubmed-meshheading:11426558-Lomustine,
pubmed-meshheading:11426558-Lymphatic Irradiation,
pubmed-meshheading:11426558-Male,
pubmed-meshheading:11426558-Middle Aged,
pubmed-meshheading:11426558-Prednisone,
pubmed-meshheading:11426558-Procarbazine,
pubmed-meshheading:11426558-Recurrence,
pubmed-meshheading:11426558-Survival Analysis,
pubmed-meshheading:11426558-Treatment Outcome,
pubmed-meshheading:11426558-Vincristine
|
|
pubmed:year |
2001
|
|
pubmed:articleTitle |
Bleomycin, lomustine, cyclophosphamide, vincristine, procarbazine and prednisone (BLEO-CCVPP) in patients with Hodgkin's disease who relapsed after radiotherapy alone: a long-term follow-up study of the Eastern Cooperative Oncology Group (E3481).
|
|
pubmed:affiliation |
OLM Comprehensive Cancer Center, New York Medical College, Bronx 10466, USA. wiernik@jimmy.harvard.edu
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Clinical Trial, Phase II
|
